| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-08-24 |
2025-05-23 |
2024-11-22 |
2023-11-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY |
• – – |
2025-10-22 |
4 |
D |
$0.66 |
$29,121 |
D/D |
(44,122) |
704,121 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
• – – |
2025-10-22 |
4 |
D |
$0.66 |
$28,869 |
D/D |
(43,741) |
722,348 |
|
- |
|
| Duraibabu Prathyusha |
PRINCIPAL FINANCIAL OFFICER |
• – – |
2025-10-22 |
4 |
D |
$0.66 |
$29,849 |
D/D |
(45,225) |
699,262 |
|
- |
|
| Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
• • – |
2025-10-22 |
4 |
D |
$0.66 |
$83,787 |
D/D |
(126,950) |
2,057,022 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-10-22 |
4 |
D |
$0.66 |
$4,427 |
D/D |
(6,708) |
194,514 |
|
- |
|
| Jain Nikunj |
Principal Accounting Officer |
• – – |
2025-10-22 |
4 |
D |
$0.66 |
$4,427 |
D/D |
(6,708) |
246,295 |
|
- |
|
| Jain Nikunj |
Principal Accounting Officer |
• – – |
2025-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
253,003 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-08-24 |
4 |
D |
$0.59 |
$1,051 |
D/D |
(1,792) |
744,487 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
• – – |
2025-08-24 |
4 |
D |
$0.59 |
$1,051 |
D/D |
(1,792) |
766,089 |
|
- |
|
| Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
• • – |
2025-08-24 |
4 |
D |
$0.59 |
$4,390 |
D/D |
(7,488) |
2,183,972 |
|
- |
|
| Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY |
• – – |
2025-08-24 |
4 |
D |
$0.59 |
$841 |
D/D |
(1,434) |
748,243 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-08-24 |
4 |
D |
$0.59 |
$424 |
D/D |
(723) |
201,222 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-07-22 |
4 |
D |
$0.48 |
$3,218 |
D/D |
(6,708) |
201,945 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
• – – |
2025-07-22 |
4 |
D |
$0.48 |
$15,289 |
D/D |
(31,866) |
767,881 |
|
- |
|
| Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
• • – |
2025-07-22 |
4 |
D |
$0.48 |
$60,911 |
D/D |
(126,950) |
2,191,460 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-07-22 |
4 |
D |
$0.48 |
$15,289 |
D/D |
(31,866) |
746,279 |
|
- |
|
| Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY |
• – – |
2025-07-22 |
4 |
D |
$0.48 |
$15,289 |
D/D |
(31,866) |
749,677 |
|
- |
|
| Meyers James R |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
99,600 |
|
- |
|
| Beers Courtney |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
82,650 |
|
- |
|
| Markels John |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
96,384 |
|
- |
|
| Carey Robert |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
99,600 |
|
- |
|
| Horn Margaret A |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
82,650 |
|
- |
|
| Hillan Kenneth |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
99,600 |
|
- |
|
| Smith Karen L. |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
102,100 |
|
- |
|
| Parker H Stewart |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
112,600 |
|
- |
|
446 Records found
|
|
Page 1 of 18 |
|
|
0.04 (6.83%) 
